Paltusotine(oral SST2 agonist)


In development for the treatment of acromegaly and neuroendocrine tumors (NETs), our lead product candidate establishes a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist.

CRN04777(Oral SST5 Agonist)


This is the first oral, selective, somatostatin type 5 (SST5) receptor agonist designed to treat congenital hyperinsulinism (congenital HI).

Oral ACTH Antagonist


This is the first oral, selective ACTH antagonist in development for the treatment of Cushing’s disease and other diseases of excess ACTH, such as congenital adrenal hyperplasia (CAH).